LEO Pharma Strengthens Global Leadership Team With Appointment of Jörg Möller as Executive Vice President, Global Research and Development

LEO Pharma Strengthens Global Leadership Team With Appointment of Jörg Möller as Executive Vice President, Global Research and Development




LEO Pharma Strengthens Global Leadership Team With Appointment of Jörg Möller as Executive Vice President, Global Research and Development

BALLERUP, Denmark–(BUSINESS WIRE)–LEO Pharma A/S today announced that Jörg Möller will join its Global Leadership Team as Executive Vice President, Global Research and Development, effective January 1, 2021.

Möller joins LEO Pharma from Bayer Pharma, where he has been EVP Head of R&D and Member of the Bayer Pharma Executive Committee.

A medical doctor and Ph.D. by training, Jörg Möller brings a wealth of experience from his long international career during which he was responsible for a significant global organization with main hubs in Germany, the US, Switzerland, Japan and China. He led the entire value chain from target and drug discovery through clinical development, life-cycle-management and regulatory approvals and has brought a range of successful global product approvals. His experience spans multiple therapeutic areas including dermatology and immunology and a variety of technology platforms like biologics and cell & gene therapies. He has a solid track record of working with external partners.

Jörg Möller’s experience will help us to significantly foster our innovative pipeline which underpins our ambition to become a global leader in medical dermatology,” said Catherine Mazzacco, President and CEO of LEO Pharma.

I am excited to join LEO Pharma and inspired by its strategy and ambition. People with dermatologic medical conditions need new treatment options, and I want to bring in my experience and expertise to the R&D team at LEO Pharma so we together can contribute significantly to improving patients’ lives,” said Jörg Möller.

Jörg Möller succeeds Kim Kjøller who, as previously announced, decided to leave LEO Pharma for a CEO role at Union Therapeutics.

– Ends –

About LEO Pharma

The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries. For more information about LEO Pharma, visit www.leo-pharma.com.

Contacts

Media contacts:
Henrik Kyndlev

+45 3140 6180

hdtdk@leo-pharma.com